AC
BLUE

Avestar Capital’s bluebird bio BLUE Stock Holding History

Avestar Capital’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8
Closed -$12K – 250
2019
Q2 		$12K Hold
8
– – 0.01% 472
2019
Q1 		$15K Hold
8
– – 0.01% 411
2018
Q4 		$9K Buy
+8
New +$12.3K 0.01% 449

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Avestar Capital's BLUE Position: Q3 2019 in Review

Avestar Capital sold out of bluebird bio (BLUE) in Q3 2019, closing a stake of 8 shares — an estimated $12K sold.

Avestar Capital first reported a position in BLUE in Q4 2018 and held it in 3 quarters. The position peaked at $15K in Q1 2019. 241 funds tracked by Wall St. Rank hold BLUE as of Q3 2019.

  • Avestar Capital reported no remaining bluebird bio position as of Q3 2019 after selling out during the quarter.
  • Avestar Capital sold 8 bluebird bio shares in Q3 2019, an estimated $12K.
  • Avestar Capital first reported a position in bluebird bio in Q4 2018 and held it in 3 quarters.
  • Avestar Capital's bluebird bio position peaked at $15K in Q1 2019.
  • 241 funds tracked by Wall St. Rank held bluebird bio as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.